Literature DB >> 29505475

De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients.

Stefano Gitto1, Nicola de Maria1, Fabrizio di Benedetto2, Giuseppe Tarantino2, Valentina Serra2, Lorenzo Maroni3, Matteo Cescon3, Antonio D Pinna3, Filippo Schepis1, Pietro Andreone4, Erica Villa1.   

Abstract

OBJECTIVE: Patients who have undergone transplantation often develop metabolic syndrome (MetS) and de-novo nonalcoholic fatty liver disease (NAFLD). Our aim was to evaluate the impact of metabolic disease on cardiovascular and neoplastic risk and survival. PATIENTS AND METHODS: Data from patients who underwent transplantation between 2000 and 2005 in two Italian transplant centers were analyzed. Cox regression analysis was carried out for predictors of de-novo NAFLD and nonalcoholic steatohepatitis (NASH), cardiovascular events, de-novo extrahepatic cancers, and survival. Survival analysis was completed using the Kaplan-Meier method. A P value less than 0.05 was considered significant for all tests.
RESULTS: De-novo NAFLD was found in one-fifth of 194 patients. Patients with de-novo NAFLD fulfilled the criteria of MetS in 74.4% of cases, while patients without de-novo NAFLD in 29.8% (P=0.000). On multivariate analysis, MetS correlated independently with de-novo NAFLD and this emerged as an independent predictor of cardiovascular events and as a relevant risk factor for solid extrahepatic cancer. Data on smoking habits, which represent a consolidated risk factor for cardiovascular events and cancer in both the general population and patients who have undergone transplantation, are not available. In the subset of histologically proven NASH, it was the strongest predictor of long-term survival (hazard ratio=4.133, 95% confidence interval: 1.385-12.331, P=0.011).
CONCLUSION: Post-transplant NAFLD represented a strong risk factor for cardiovascular atherosclerotic disease and solid extrahepatic cancer, whereas de novo histologically proven NASH was an independent predictor of long-term mortality.

Entities:  

Mesh:

Year:  2018        PMID: 29505475     DOI: 10.1097/MEG.0000000000001105

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

Review 1.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

Review 2.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

3.  Nonalcoholic Fatty Liver Disease in Living Donor Liver Transplant Recipients: A Histology-Based Study.

Authors:  Narendra S Choudhary; Neeraj Saraf; Swapnil Dhampalwar; Saurabh Mishra; Dheeraj Gautam; Lipika Lipi; Amit Rastogi; Prashant Bhangui; Rohan J Chaudhary; Ankur Gupta; Kamal Yadav; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2022-05-05

Review 4.  Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.

Authors:  Naga Swetha Samji; Rajanshu Verma; Krishna Chaitanya Keri; Ashwani K Singal; Aijaz Ahmed; Mary Rinella; David Bernstein; Manal F Abdelmalek; Sanjaya K Satapathy
Journal:  Dig Dis Sci       Date:  2019-07-16       Impact factor: 3.199

5.  NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities.

Authors:  Liyun Yuan; Ani Kardashian; Monika Sarkar
Journal:  Curr Hepatol Rep       Date:  2019-11-18

Review 6.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

7.  Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation.

Authors:  Oren Shaked; Jack Demetris; Josh Levitsky; Sandy Feng; Bao-Li Loza; Jeff Punch; Jorge Reyes; Goran Klintmalm; Whitney Jackson; Michele DesMarais; Peter Sayre; Abraham Shaked; K Rajender Reddy
Journal:  Transplantation       Date:  2022-01-01       Impact factor: 5.385

Review 8.  Noninvasive markers of liver steatosis and fibrosis after liver transplantation - Where do we stand?

Authors:  Ivana Mikolasevic; Sanja Stojsavljevic; Filip Blazic; Maja Mijic; Delfa Radic-Kristo; Toni Juric; Nadija Skenderevic; Mia Klapan; Andjela Lukic; Tajana Filipec Kanizaj
Journal:  World J Transplant       Date:  2021-03-18

Review 9.  De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation.

Authors:  Ma Ai Thanda Han; Raquel Olivo; Catherine J Choi; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2021-12-27

10.  Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements.

Authors:  Ivana Mikolasevic; Goran Hauser; Maja Mijic; Viktor Domislovic; Delfa Radic-Kristo; Zeljko Krznaric; Melanija Razov-Radas; Tajana Pavic; Marija Matasin; Tajana Filipec Kanizaj
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.